Krebs Biochemicals and Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various produ… Read more
Krebs Biochemicals and Industries Limited (KREBSBIO) - Total Liabilities
Latest total liabilities as of December 2025: ₹3.27 Billion INR
Based on the latest financial reports, Krebs Biochemicals and Industries Limited (KREBSBIO) has total liabilities worth ₹3.27 Billion INR as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Krebs Biochemicals and Industries Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Krebs Biochemicals and Industries Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Krebs Biochemicals and Industries Limited Competitors by Total Liabilities
The table below lists competitors of Krebs Biochemicals and Industries Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bio Essence Corporation
PINK:BIOE
|
USA | $3.29 Million |
|
OSI SYSTEMS - Dusseldorf Stock Exchang
DU:OS2
|
Germany | €1.33 Billion |
|
ECM Libra Financial Group Bhd
KLSE:2143
|
Malaysia | RM78.99 Million |
|
4LE
F:4LE
|
Germany | €536.26K |
|
Fobi AI Inc
OTCQB:FOBIF
|
USA | $2.62 Million |
|
First National Bank Alaska
OTCQX:FBAK
|
USA | $4.68 Billion |
|
Tourn International AB
ST:TOURN
|
Sweden | Skr23.03 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Krebs Biochemicals and Industries Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Krebs Biochemicals and Industries Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Krebs Biochemicals and Industries Limited (2006–2025)
The table below shows the annual total liabilities of Krebs Biochemicals and Industries Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹3.15 Billion | +6.01% |
| 2024-03-31 | ₹2.97 Billion | +8.36% |
| 2023-03-31 | ₹2.74 Billion | +3.60% |
| 2022-03-31 | ₹2.65 Billion | +31.17% |
| 2021-03-31 | ₹2.02 Billion | +27.18% |
| 2020-03-31 | ₹1.59 Billion | +1.37% |
| 2019-03-31 | ₹1.57 Billion | +9.05% |
| 2018-03-31 | ₹1.44 Billion | +19.12% |
| 2017-03-31 | ₹1.21 Billion | +16.63% |
| 2016-03-31 | ₹1.03 Billion | +14.69% |
| 2015-03-31 | ₹901.62 Million | -32.80% |
| 2014-03-31 | ₹1.34 Billion | +3.47% |
| 2013-03-31 | ₹1.30 Billion | +3.38% |
| 2012-03-31 | ₹1.25 Billion | +7.92% |
| 2011-03-31 | ₹1.16 Billion | +3.93% |
| 2010-03-31 | ₹1.12 Billion | -6.81% |
| 2009-03-31 | ₹1.20 Billion | +9.76% |
| 2008-03-31 | ₹1.09 Billion | -9.83% |
| 2007-03-31 | ₹1.21 Billion | -16.01% |
| 2006-03-31 | ₹1.44 Billion | -- |